PT-141 is the research-chemical name for bremelanotide, a synthetic melanocortin receptor agonist developed from Melanotan II by removing the side effect responsible for its prolonged, unwanted erections. Bremelanotide is FDA-approved as Vyleesi, an on-demand 1.75 mg subcutaneous injection for hypoactive sexual desire disorder in premenopausal women. It has no FDA approval, and no published Phase 3 trial, for use in men, despite that being how it most often circulates outside its approved indication.
Ask about PT-141
Research snapshot
| Category | Current information |
|---|---|
| Peptide category | Synthetic cyclic heptapeptide, melanocortin receptor (MC1R/MC4R) agonist |
| Primary research interest | Hypoactive sexual desire disorder (HSDD) in premenopausal women (approved indication); male sexual dysfunction (widely circulated, unapproved) |
| Highest available evidence | Tier 1: randomized, placebo-controlled Phase 3 trials (RECONNECT program) supporting FDA approval |
| Human research available | Yes, for the approved female HSDD indication; no published Phase 3 trial in men |
| Development status | Fully approved pharmaceutical (Vyleesi) |
| Regulatory status | FDA-approved for HSDD in premenopausal women only; not approved for use in men |
Technical identity
| Technical property | Information |
|---|---|
| Primary name | PT-141 (research-chemical name for bremelanotide) |
| Alternative names | Bremelanotide, Vyleesi (brand), PT141 |
| Peptide sequence | Cyclic heptapeptide, derived from Melanotan II by removing the C-terminal amide |
| Amino-acid length | 7 (cyclic) |
| Molecular formula | C50H68N14O10 |
| Molecular weight | ≈997.2 g/mol |
| CAS Registry Number | 189691-06-3 |
| PubChem CID | 9941379 |
| Peptide class | Melanocortin receptor agonist (MC1R, MC4R) |
| Primary biological target | Melanocortin receptors (MC1R, MC4R), central pathways involved in sexual desire |
| Developer / originator | Derived from Melanotan II; developed by Palatin Technologies |
| Development status | Approved prescription drug (Vyleesi) for HSDD in premenopausal women |
What it is
PT-141 is the research-chemical name for bremelanotide, a synthetic cyclic heptapeptide melanocortin receptor agonist (MC1R and MC4R). It was developed from Melanotan II by removing the C-terminal amide, a change made specifically to reduce Melanotan II’s prolonged erection and nausea side effects. Bremelanotide is FDA-approved, under the brand name Vyleesi, as an on-demand subcutaneous injection for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, and it is not approved for any use in men.
Figures in this table summarize dosing described in the FDA-approved prescribing information, alongside what circulates online. Their inclusion documents what is reported and does not establish what any individual reader should take.
| Use | Route | Amount | Frequency | Evidence category |
|---|---|---|---|---|
| HSDD in premenopausal women (approved, Vyleesi) | Subcutaneous | 1.75 mg | As needed, ≥45 min before activity; no more than once per 24 hrs, no more than 8x/month | FDA-approved prescribing information (RECONNECT Phase 3 program) |
| Male sexual dysfunction (human research) | Not reported | Not established | Not reported | No FDA approval and no published Phase 3 trial in men |
| General use, as commonly circulated online (incl. off-label male use) | Subcutaneous | 1 to 2 mg per dose | As needed, sometimes more frequent than the approved limit | Community / vendor reported: roughly matches the approved dose but tested population and frequency differ |
Potential benefits and research applications
Hypoactive sexual desire disorder in premenopausal women, the FDA-approved indication
The RECONNECT Phase 3 program, two 24-week randomized, double-blind, placebo-controlled trials, plus a 52-week open-label extension, established improved sexual desire and reduced sexual distress scores in premenopausal women with HSDD using an as-needed 1.75 mg subcutaneous dose.
Evidence: has been shown in randomized, placebo-controlled Phase 3 human trials (Tier 1, published human clinical evidence, FDA-approved indication).
Sexual dysfunction in men, a widely circulated use with no matching approval or trial base
PT-141 is commonly used and discussed for erectile function and libido in men, extrapolating from its melanocortin mechanism and its shared lineage with Melanotan II. No FDA approval and no published Phase 3 trial for male sexual dysfunction exists.
Evidence: has been reported anecdotally (Tier 6, community-reported information); has not been established by any registered or published human trial in men.
The approval and its evidence
FDA approval rested on the RECONNECT program, two parallel 24-week randomized, double-blind, placebo-controlled Phase 3 trials (studies 301 and 302) in premenopausal women with HSDD, using a 1.75 mg subcutaneous dose self-administered at least 45 minutes before anticipated sexual activity, as needed, no more than once in 24 hours and no more than 8 times per month. A 52-week open-label extension in patients who completed the core trials, published in 2019, reported sustained improvement in desire scores and no new safety signals; the most common treatment-related adverse events were nausea (40.4% over the full extension), flushing (20.6%) and headache (12.0%).
Nausea is dose-limiting and common enough that the label recommends against use in patients with uncontrolled hypertension or known cardiovascular disease, and bremelanotide transiently raises blood pressure after each dose.
What is not established
Efficacy or safety in men. Bremelanotide has no FDA approval and no published Phase 3 program for male sexual dysfunction; interest in “PT-141 for men” circulates in research-peptide material without the trial base that exists for the approved female indication.
Whether more frequent dosing than the approved as-needed schedule, as sometimes described in circulating protocols, changes the tachyphylaxis, blood-pressure or nausea profile established in the pivotal trials, which tested a strict as-needed limit.
Frequently asked questions
What is PT-141?
PT-141 is the research-chemical name for bremelanotide, an FDA-approved melanocortin receptor agonist sold as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
How does PT-141 work?
It activates MC1R and MC4R melanocortin receptors, a mechanism believed to act on central pathways involved in sexual desire, distinct from how erectile-dysfunction drugs like sildenafil work on blood flow.
What dosage has been studied in humans?
The approved regimen is 1.75 mg subcutaneously, as needed at least 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than 8 times per month, as tested in the RECONNECT Phase 3 trials.
What dosage commonly circulates online?
Circulating material describes 1 to 2 milligrams subcutaneously as needed, roughly matching the approved dose, but often for male use and sometimes at a higher frequency than the approved once-per-24-hours, 8-times-per-month limit.
Has PT-141 been studied in humans?
Yes, extensively, in the FDA-approved indication (HSDD in premenopausal women). No published Phase 3 trial exists for use in men.
Is PT-141 approved for use?
Yes, as Vyleesi, for hypoactive sexual desire disorder in premenopausal women only. It is not approved for use in men.
What routes of administration are reported?
Subcutaneous injection is the approved and universally reported route.
Does PT-141 work for men?
This has not been established by any FDA-approved trial. Interest in male use circulates in research-peptide material without the Phase 3 trial base that exists for the approved female indication.
What side effects have been reported?
The most common treatment-related adverse events in the pivotal trials were nausea (40.4% over the full extension), flushing (20.6%) and headache (12.0%). It transiently raises blood pressure after each dose and is not recommended for patients with uncontrolled hypertension or known cardiovascular disease.
What remains unknown about PT-141?
Efficacy and safety in men, for which no FDA approval or Phase 3 trial exists, and whether more frequent or scheduled dosing than the approved as-needed limit changes its tachyphylaxis, blood-pressure or nausea profile.
Bottom line
PT-141 is a genuine FDA-approved drug, bremelanotide, with a solid Phase 3 trial base, but only for one specific indication: hypoactive sexual desire disorder in premenopausal women, at a strict as-needed dose. The male-use and higher-frequency protocols that dominate how it circulates outside that approval have no matching human trial data behind them.
What circulates E5
| Reported use | Route | Amount reported | Frequency | Reported length |
|---|---|---|---|---|
| Libido/sexual function, general (including off-label male use) | Subcutaneous | 1 to 2 mg per dose | As needed, sometimes more frequent than the approved limit | Ongoing |
Circulating dosing for PT-141, 1 to 2 mg subcutaneously as needed, roughly matches the FDA-approved 1.75 mg dose for the approved indication (HSDD in premenopausal women). Where it diverges is population and frequency: circulating material commonly describes male use and more frequent dosing than the approved once-per-24-hours, 8-times-per-month limit, neither of which was tested in the pivotal trials this drug was approved on.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Sources
- Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019;134(5):909-917. Human, RECONNECT open-label extension, n=684, 1.75 mg SC as needed. PMID 31599847
- US Food and Drug Administration. VYLEESI (bremelanotide) injection, prescribing information. Approved indication: HSDD in premenopausal women. 1.75 mg SC as needed. FDA NDA 210557
Compare PT-141 with related compounds
Research area: Sexual health and melanocortin.